REPLIGEN CORP Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
REPLIGEN CORP (RGEN) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value of $153.13 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue · last filed 2026-07-29
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2026-03-31 was $165.09, a 7.49% decline year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2025-03-31 was $178.46, a 4.36% decline year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2024-03-31 was $186.59, a 4.67% decline year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2023-03-31 was $195.74.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2025 was $172.86, a 8.88% decline from fiscal 2024.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2024 was $189.71, a 6.69% increase from fiscal 2023.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2023 was $177.81, a 10.41% increase from fiscal 2022.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2022 was $161.05.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $153.13 10-Q · filed 2026-07-29 | |||
| 2026-03-31 | $165.09 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $172.86 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $172.55 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $171.85 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $178.46 10-Q · filed 2025-04-29 | |||
| 2024-12-31 | $189.71 10-K · filed 2025-03-14 | |||
| 2024-09-30 | $190.45 10-Q · filed 2024-11-18 | |||
| 2024-06-30 | $189.15 10-Q/A · filed 2024-11-18 | |||
| 2024-03-31 | $186.59 10-Q/A · filed 2024-11-18 | |||
| 2023-12-31 | $177.81 10-K/A · filed 2024-11-18 | |||
| 2023-09-30 | $179.53 10-Q/A · filed 2024-11-18 | |||
| 2023-06-30 | $182.56 10-Q/A · filed 2024-11-18 | |||
| 2023-03-31 | $195.74 10-Q/A · filed 2024-11-18 | |||
| 2022-12-31 | $161.05 10-K · filed 2023-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |